Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;184(3):907-12.
doi: 10.1016/j.juro.2010.05.029.

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy

Affiliations

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy

Andrew J Vickers et al. J Urol. 2010 Sep.

Abstract

Purpose: Prostate specific antigen velocity has been proposed as a marker to aid in prostate cancer detection. We determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy.

Materials and methods: We identified 1,837 men who participated in the Göteborg or Rotterdam section of the European Randomized Screening study of Prostate Cancer and who underwent 1 or more subsequent prostate biopsies after an initial negative finding. We evaluated whether prostate specific antigen velocity improved predictive accuracy beyond that of prostate specific antigen alone.

Results: Of the 2,579 repeat biopsies 363 (14%) were positive for prostate cancer, of which 44 (1.7%) were high grade (Gleason score 7 or greater). Prostate specific antigen velocity was statistically associated with cancer risk but had low predictive accuracy (AUC 0.55, p <0.001). There was some evidence that prostate specific antigen velocity improved AUC compared to prostate specific antigen for high grade cancer. However, the small increase in risk associated with high prostate specific antigen velocity (from 1.7% to 2.8% as velocity increased from 0 to 1 ng/ml per year) had questionable clinical relevance.

Conclusions: Men with prior negative biopsy are at lower risk for prostate cancer at subsequent biopsies with high grade disease particularly rare. We found little evidence to support prostate specific antigen velocity to aid in decisions about repeat biopsy for prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: Dr. Hans Lilja holds patents for free PSA and hK2 assays.

Figures

Figure 1
Figure 1
Predicted probability of a positive biopsy by PSA velocity, with adjustment for the number of prior negative biopsies. The shaded region represents the population-based quartiles of PSA velocity.
Figure 2
Figure 2
Predicted probability of a high grade disease on biopsy by PSA velocity, with adjustment for the number of prior negative biopsies. The shaded region represents the population-based quartiles of PSA velocity.

Similar articles

Cited by

References

    1. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035. - PMC - PubMed
    1. Dotan ZA, Bianco FJ, Jr, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005;23:1962. - PMC - PubMed
    1. Robinson D, Sandblom G, Johansson R, et al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology. 2008;72:903. - PubMed
    1. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191. - PubMed
    1. Loeb S, Roehl KA, Catalona WJ, et al. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol. 2007;177:899. - PubMed

Publication types

Substances